Results 81 to 90 of about 18,310 (204)

Risk of Serious Adverse Events and Death With Low‐Dose Methotrexate Versus Hydroxychloroquine in Adults Receiving Dialysis

Seminars in Dialysis, EarlyView.
ABSTRACT Background Several case reports have linked low‐dose methotrexate to serious adverse events, including death, in dialysis patients. We compared the risk of serious adverse events in dialysis patients initiating low‐dose methotrexate versus hydroxychloroquine.
Flory T. Muanda, Peter G. Blake, Matthew A. Weir, Fatemeh Ahmadi, Mohammad Ali Omrani, Sheikh S. Abdullah, Eric McArthur, Jessica M. Sontrop, Brad L. Urquhart, Amit X. Garg   +9 more
wiley   +1 more source

Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?

Research and Practice in Thrombosis and Haemostasis
Janus kinase inhibitors (JAKis) have revolutionized the treatment landscape for various inflammatory and autoimmune diseases since their introduction in 2012. The expanded indications of JAKis have raised concerns about the associated risk of thrombosis,
Yachar Dawudi, Samuel Benarroch, Hélène Helfer, David M. Smadja, Isabelle Mahé   +4 more
doaj   +1 more source

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 684-691, September 2026.
Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu, Bella D. Ianni, Richard O. Day, Jacques Raubenheimer, Christine Y. Lu   +4 more
wiley   +1 more source

Evaluation of a Novel Electric Health Record Sidecar Application to Display Rheumatoid Arthritis Clinical Outcomes During Clinic Visits: Results of a Stepped‐Wedge Cluster Randomized Pragmatic Trial

Arthritis Care &Research, Volume 78, Issue 8, Page 1006-1015, August 2026.
Objective We developed a novel electronic health record sidecar application to visualize key rheumatoid arthritis (RA) outcomes, including disease activity, physical function, and pain, via a patient‐facing graphical interface designed for use during outpatient visits (“RA PRO dashboard”).
Gabriela Schmajuk, Jing Li, Cathy Nasrallah, Cherish Wilson, Alicia Hamblin, Christine Hariz, Cammie Young, Stephen Shiboski, Emma Kersey, Mary Nakamura, Judith F. Ashouri, Mehrdad Matloubian, Andrew J. Gross, Jennifer Barton, Beth Berrean, Jonathan Prugh, Jinoos Yazdany   +16 more
wiley   +1 more source

The role of disease-modifying antirheumatic drugs in the implementation of the «treat-to-target» strategy for rheumatoid arthritis

Каразінський імунологічний журнал
Background. Rheumatoid arthritis is a chronic systemic autoimmune disease that remains one of the leading causes of disability worldwide. Effective management of this condition requires a modern approach focused on the early achievement of therapeutic ...
F.V. Hladkykh
doaj   +1 more source

Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor‐Induced Autoimmunity

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
The rapid integration of immune checkpoint inhibitors (ICIs) into standard oncology protocols has birthed a new frontier in clinical rheumatology: immune‐related adverse events (irAEs). By disrupting the programmed cell death‐1 (PD‐1)/PD‐L1 and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) axes to restore antitumor T cell activity, these ...
Xizi Hu, Ji Eun Ryoo, Brian S. Henick, Adam Mor   +3 more
wiley   +1 more source

Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents.

JAMA Netw Open, 2022
Desai RJ, Varma VR, Gerhard T, Segal J, Mahesri M, Chin K, Horton DB, Kim SC, Schneeweiss S, Thambisetty M.   +9 more
europepmc   +1 more source

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1755-1764, August 2026.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source

Treatment of a Large Cohort of Childhood Chronic Noninfectious Uveitis in a Multicentric Large Study: Adalimumab Versus Methotrexate as First‐Line Therapy

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1789-1797, August 2026.
Objective Treatment of childhood chronic idiopathic uveitis (cCIU) is predominantly based on studies in juvenile idiopathic arthritis–associated uveitis and expert opinion. Our aim was to report the treatment outcomes of our cohort of cCIU. Methods Retrospective multicenter study involving the rheumatology and ophthalmology units at Florence, Italy ...
Ilaria Maccora, Catherine Guly, Cinzia de Libero, Giulia Carreras, Athimalaipet V. Ramanan, Gabriele Simonini   +5 more
wiley   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1674-1686, August 2026.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source